Skip to content

Geron

US · GERN #3440 by market cap
1.20 -0.01 -0.83%
Live - 5344 symbols - heartbeat 211s ago · 2026-10-08 08:45
Pre-market 1.19 -0.77%
After-hours 1.20 0.00%
Overnight 1.21 +0.83%
Market cap
770.97M
P/B
3.53
EPS
-0.13
Reader sentiment Are you bullish or bearish on GERN?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 3.53 Cheap vs history 28th percentile
5-year average 5.52 · #322 of 513 in Biotechnology
P/E ratio -10.91 Cheap vs history 30th percentile
5-year average -8.43 · forward 104.86
P/S ratio 3.77 Cheap vs history 1st percentile
5-year average 1,399.63 · forward 2.69 · #84 of 387 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Geron (GERN) 770.97M -10.91 3.53 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value1.30 Economic moatNone UncertaintyHigh

Trading 7.9% below Morningstar's fair value estimate.

Fair value

Geron Corp receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 8% discount to our quantitative fair value estimate of $1.30 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's balance sheet strengthens our quantitative valuation. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's EBITDA/interest coverage ratio of -1.7 falls in the bottom 20% globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be cheap.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -4.3%, a core component of profitability, sits in the bottom 20% globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 08:45:12 · For reference only, not investment advice and not tailored to your situation.